Lovo-cel Gene Therapy Program Suspended for Adolescents With SCD

Lovo-cel Gene Therapy Program Suspended for Adolescents With SCD

314944

Lovo-cel Gene Therapy Program Suspended for Adolescents With SCD

A clinical program for lovotibeglogene autotemcel (lovo-cel), an investigational gene therapy for sickle cell disease (SCD), has been suspended for patients under 18 by the U.S. Food and Drug Administration (FDA). Bluebird Bio announced the partial suspension of its program due to an ongoing investigation into persistent, nontransfusion-dependent anemia — a condition in which an individual lacks enough healthy red blood cells to carry oxygen to body tissues — in an adolescent patient following treatment…

You must be logged in to read/download the full post.